Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 19/20 | 0.55 |
| ▸ | GUCY1B1 | Q02153 | 19/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038299 | 1.00 | GUCY1A1 (0.55) | GUCY1A1GUCY1B1KDM4EPOLBHPGD | |
| SCHEMBL8401905 | 0.92 | GUCY1A1 (0.53) | GUCY1A1GUCY1B1 | |
| SCHEMBL3127111 | 0.92 | GUCY1A1 (0.53) | GUCY1A1GUCY1B1 | |
| SCHEMBL3256219 | 0.92 | GUCY1A1 (0.53) | GUCY1A1GUCY1B1 | |
| SCHEMBL16835706 | 0.88 | GUCY1A1 (0.62) | GUCY1A1GUCY1B1 | |
| SCHEMBL16835708 | 0.88 | GUCY1A1 (0.57) | GUCY1A1GUCY1B1KDM4EPOLBHPGD | |
| SCHEMBL3043967 | 0.88 | GUCY1A1 (0.52) | GUCY1A1GUCY1B1 | |
| SCHEMBL3039141 | 0.88 | GUCY1A1 (0.52) | GUCY1A1GUCY1B1 | |
| SCHEMBL3039138 | 0.88 | GUCY1A1 (0.52) | GUCY1A1GUCY1B1 | |
| SCHEMBL3039341 | 0.88 | GUCY1A1 (0.69) | GUCY1A1GUCY1B1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401265-B1 | DERIVATIVES OF 1-PYRI(MID)IN-2-YL-PYRAZOLE-4-CARBOXYLIC ACID WHICH ARE USEFUL FOR THERAPY OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME (US) | 2016-09-14 | — | — | EP | disclosed |
| US-8507512-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A1, GUCY1A2 | GUCY1A1 2/4885GUCY1B1 1/4885KDM4E 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.